05/24/2017

NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Bladder Cancer.

NCCN has published updates to the NCCN Guidelines^® and the NCCN Compendium^® for Bladder Cancer. These NCCN Guidelines^® are currently available as Version 4.2017. 

• Principles of Systemic Therapy (BL-G 2 of 4)
  • Subsequent systemic therapy for locally advanced or metastatic disease
    • “Avelumab” was added as a standard regimen option with a category 2A designation for:
    • Bladder cancer
    • Upper GU tract tumors: Renal pelvis
    • Upper GU tract tumors: Urothelial carcinoma of the ureter
    • Urothelial carcinoma of the prostate
    • Primary carcinoma of the urethra (urothelial carcinomas only).
    • The Discussion section has been updated to reflect the changes in the algorithm. (MS-1)

*For your reference, the previous update (Version 3.2017) to the NCCN Guidelines for Bladder Cancer, published on May 8, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.